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Abstract
CD4
+ T-cells from gut-associated lymphoid tissues (GALT) are major targets for HIV-1 infection. Recruitment of excess
effector CD8
+ T-cells in the proximity of target cells is critical for the control of viral replication. Here, we investigated the
colocalization potential of HIV-specific CD8
+ and CD4
+ T-cells into the GALT and explored the role of retinoic acid (RA) in
regulating this process in a cohort of HIV-infected subjects with slow disease progression. The expression of the gut-homing
molecules integrin b7, CCR6, and CXCR3 was identified as a ‘‘signature’’ for HIV-specific but not CMV-specific CD4
+ T-cells
thus providing a new explanation for their enhanced permissiveness to infection in vivo. HIV-specific CD8
+ T-cells also
expressed high levels of integrin b7 and CXCR3; however CCR6 was detected at superior levels on HIV-specific CD4
+ versus
CD8
+ T-cells. All trans RA (ATRA) upregulated the expression of integrin b7 but not CCR6 on HIV-specific T-cells. Together,
these results suggest that HIV-specific CD8
+ T-cells may colocalize in excess with CD4
+ T-cells into the GALT via integrin b7
and CXCR3, but not via CCR6. Considering our previous findings that CCR6
+CD4
+ T-cells are major cellular targets for HIV-
DNA integration in vivo, a limited ability of CD8
+ T-cells to migrate in the vicinity of CCR6
+CD4
+ T-cells may facilitate HIV
replication and dissemination at mucosal sites.
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Introduction
The human immunodeficiency virus type 1 (HIV) epidemic
remains a major global health problem despite major advances
made since the discovery of the virus in 1983 [1]. The HIV
infection has been known to be associated to a gastrointestinal
pathology since the beginning of the epidemic [2,3]. Recent
studies in HIV-infected individuals and simian models of infection
demonstrated that depletion of CD4
+ T-cells from gut-associated
lymphoid tissues (GALT) occurs very early upon infection
[4,5,6,7]. Memory CD4
+ T-cells, expressing the HIV coreceptor
CCR5, massively infiltrate the GALT and are preferential targets
of viral replication and depletion [8,9]. The alteration of GALT
homeostasis in HIV-infected individuals leads to the impairment
of mucosal immunity and microbial translocation from the gut,
which can drive chronic immune activation [10,11]. Despite a
partial restoration of mucosal immunity in the GALT of
individuals receiving long-term antiretroviral therapies (ART)
[12,13], viral reservoirs persist in different cellular and anatomic
compartments and represent a major barrier to HIV eradication
[14].
A small fraction of HIV-infected individuals control disease
progression for a long period of time in the absence of ART and
are called long-term nonprogressors (LTNPs) or slow progressors
[15]. The LTNPs subjects are generally defined as HIV-infected
individuals who remain clinically asymptomatic with non-
declining CD4 counts (.500 cells/ml), and undetectable plasma
viral loads (,50–75 HIV RNA copies/ml) for .10 years [16].
However, LTNPs are very heterogeneous and include individuals
with virological and/or immunological control. Virological
controllers (also called ‘‘elite controllers’’) are characterized by
undetectable plasma viral loads regardless of their CD4 counts,
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32964while immunological controllers maintain their CD4 counts in the
normal range despite detectable plasma viral loads [15,16].
Mechanisms involved in the control of disease progression in
LTNPs have been linked to host genetic factors controlling the
quality of innate and adaptive immunity [17,18]. The ability of
CD8
+ T-cells to control HIV replication via cytotoxic and non-
cytotoxic mechanisms is well documented [19,20,21]. However,
viral reservoirs persist in LTNPs [22,23], pointing out the inability
of the immune system to achieve HIV eradication. This is
consistent with the finding that the GALT remains an important
target of HIV replication in LTNPs with functional alterations in
this compartment contributing to slow disease progression [24].
Nevertheless, the existence of a group of HIV-exposed uninfected
individuals, in which HIV-specific CD8
+ T-cell responses were
detected in the cervical mucosa [25], provides proof that
protective immunity against HIV can be mounted under specific
conditions. Thus, the mechanisms of immune protection against
HIV require further investigations.
HIV infection is initiated by a small viral founder population
that undergoes mutations to escape T-cell responses [26,27,28].
Limiting viral dissemination from the portal site of entry very early
after infection via robust anti-viral mechanisms is of paramount
importance to prevent the establishment of a chronic HIV
infection [28]. Recent studies using a model of simian immuno-
deficiency virus (SIV)-infection and in situ visualization techniques
demonstrated that SIV-specific CD8
+ T-cells (effectors) are
recruited into the vaginal mucosa and lymph nodes in close
proximity to SIV-infected CD4
+ T-cells (targets) [29]. The spatial
proximity of excess effectors versus target cells appears to be critical
for the control of SIV replication and dissemination in vivo [29]. By
analogy, the colocalization potential of HIV-specific CD8
+ and
CD4
+ T-cells into tissues such as the GALT might determine the
extent of viral dissemination and the outcome of disease
progression.
Trafficking of peripheral blood T-cells into the GALT is
mediated via specific adhesion molecules and chemokine receptors.
The integrin a4b7 binds to the mucosal addressin cell adhesion
molecule-1 (MadCAM-1) expressed on gut endothelial cells and
allows cells to cross the endothelial barrier [30]. The integrin aEb7
binds to the E-cadherin expressed on the basolateral surface of
intestinal epithelial cells and contributes to cell retention in the
intraepithelial compartment [31]. The CCR6 is important in the
recruitment of T-cells into Peyer’s Patches [32,33,34], while
CCR9 mediates T-cell infiltration into lamina propria [35,36,37].
The CCR5 and CXCR3 binding chemokines also regulate
infiltration of T-cells into the gut [38,39]. Previous studies
reported the expression of gut-homing molecules on HIV-specific
CD8
+ or CD4
+ T-cells. The HIV-specific CD4
+ T-cells express
the integrin b7 and CCR5 [40,41], while HIV-specific CD8
+ T-
cells from the gut express CCR5 and integrin aEb7 [42]. In
addition, a fraction of HIV-specific CD4
+ and CD8
+ T-cells
express CCR6 [43].
Results from our group and those published by others identified
CCR6 as a marker for memory CD4
+ T-cells that are highly
permissive to HIV infection in vitro [44,45] and carry superior
levels of integrated HIV-DNA in vivo [44,45]. Also, we demon-
strated that treatment with retinoic acid (RA), a metabolite of
vitamin A responsible for the imprinting for gut homing [46,47],
significantly increased the permissiveness of CCR6
+ but not
CCR6
2 CD4
+ T-cells to HIV replication by acting at entry
(CCR5 upregulation) and yet unidentified post-entry levels [48].
Thus, CCR6
+CD4
+ T-cells may represent sites for active HIV
replication into the GALT. The ability of HIV-specific CD8
+ T-
cells to be recruited into the GALT in the vicinity of CCR6
+CD4
+
T-cells remains unknown and might be predictive of an efficient
control of HIV replication in target cells at the portal sites of entry.
In this study, we investigated the potential of total and HIV-
specific CD8
+ T-cells to colocalize in excess with CCR6
+CD4
+ T-
cells and explored the role of the RA pathway in regulating the
gut-homing potential of these cells. We report here a decreased
frequency of CD8
+ and CD4
+ T-cells expressing CCR6 in the
peripheral blood of HIV-infected subjects regardless of their
clinical characteristics of disease progression. In a cohort of HIV-
infected subjects with slow disease progression, HIV-specific versus
CMV-specific CD4
+ T-cells highly express the gut-homing
markers integrin b7, CCR6, and CXCR3, suggesting a link
between enhanced permissiveness to infection in HIV-specific
CD4
+ T-cells [49] and their gut-homing potential. HIV-specific
CD8
+ T-cells also express the gut-homing molecules integrin b7
and CXCR3 but express low levels of CCR6. Thus, HIV-specific
CD8
+ T-cells may migrate into the gut via integrin b7 and
CXCR3 but exhibit a limited potential to colocalize with CD4
+ T-
cell in certain GALT sites where recruitment is dependent on
CCR6 (e.g., Peyer’s Patches) [32,33,34]. This is consistent with our
previous finding that CCR6
+CD4
+ T-cells are major sites for
HIV-DNA integration in vivo [44]. Together these results suggest
that, in addition to other previously described cellular features (e.g.,
antiviral properties, poly-functionality, and exhaustion), the co-
localization potential of HIV-specific CD4
+ and CD8
+ T-cells
might represent a new parameter to consider in order to predict
the efficacy of anti-HIV responses. Future therapeutic strategies
should aim at increasing the colocalization potential of HIV-
specific effector and target cells in mucosal tissues for a better
control of HIV dissemination from the portal sites of entry.
Materials and Methods
Study subjects
Included in the study were three groups of HIV-infected
subjects: (i) treatment-naı ¨ve with slow disease progression (SP, slow
progressors; n=14), (ii) recently infected untreated (RI; n=18),
and chronically infected under viral-suppressive anti-retroviral
therapy (CI on ART; n=20). A cohort of n=13 HIV-uninfected
subjects were included in this study as controls. Tables 1, 2, and 3
contain information on the CD4 and CD8 counts, plasma viral
loads, and time since infection of SP, RI, and CI on ART HIV-
infected subjects, respectively. At the time of leukapheresis, 9/14
SP subjects satisfied the long-term nonprogressor (LTNP) criteria,
which include .7 years time since infection, low to undetectable
plasma viral load in the absence of ART, and CD4 counts .500
cells/ml [15,16], while 5/14 SP subjects had CD4 counts ,500
cells/ml (Table 1). Among the later group, three subjects (SP 005,
011, 0108) were infected for .19-years and had detectable plasma
viral loads, while two subjects (SP 015, 0102) had undetectable
plasma viral loads and time since infection .9-years (Table 1). SP
subjects with CD4 counts ,500 cells/ml were not treated as they
lacked clinical signs of immunological failure and maintained their
plasma viral load ,10
4 HIV RNA copies/ml. CI on ART subjects
received various antiviral regimens containing a protease inhibitor,
a non-nucleoside reverse transcriptase inhibitor, or three nucleo-
side reverse transcriptase inhibitors, as we previously reported
[44]. Plasma viral load was measured using the Amplicor HIV-1
monitor ultrasensitive method (Roche). PBMCs (10
9–10
10 cells)
were collected from HIV-infected and uninfected subjects by
leukapheresis, as previously reported [50]. HIV-subjects were
recruited via the HIV Primo Infection cohort at the McGill
University Health Centre, Royal Victoria Hospital, Montreal, or
from the Canadian Cohort of HIV+ Slow Progressors.
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This study using PBMC samples from HIV-infected and
uninfected subjects, was conducted in compliance with the
principles included in the Declaration of Helsinki. This study
received approval from the Institution Review Board of the McGill
University Health Center and CHUM-Research Center, Mon-
treal, Canada. All blood donors provided written informed
consent for their participation to the study.
Table 1. Clinical parameters of HIV-infected subjects with slow disease progression (SP).
Subjects CD4 counts
# CD8 counts
# Plasma viral load
& Time since infection* ART
SP 001 860 1148 158 15 No
SP 005 435 694 1862 19 No
SP 006 991 921 ,50 15 No
SP 007 720 631 ,50 19 No
SP 008 670 475 ,50 15 No
SP 011 325 941 5370 19 No
SP 015 448 403 ,50 16 No
SP 0101 1080 1320 ,50 11 No
SP 0102 440 162 ,50 9 No
SP 0105 780 1020 15920 12 No
SP 0106 520 1790 86128 12 No
SP 0107 720 2840 1769 18 No
SP 0108 387 465 2937 21 No
SP 0109 670 740 1942 19 No
Median 670 831 964 16
#, cells/ml;
&, HIV RNA copies per ml plasma (log10);
*, years; ART, antiretroviral therapy.
doi:10.1371/journal.pone.0032964.t001
Table 2. Clinical parameters of recently HIV-infected (RI) untreated subjects.
Subjects CD4 counts
# CD8 counts
# Plasma viral load
& Time since infection* ART
RI 001 704 1081 68412 9 No
RI 002 310 350 200363 46 No
RI 003 522 366 2021 5 No
RI 004 691 1122 8714 12 No
RI 005 341 372 16883 5 No
RI 006 483 930 366646 2 No
RI 007 857 1499 93223 3 No
RI 008 475 640 56838 2 No
RI 009 338 1829 81984 4 No
RI 010 378 779 93706 2 No
RI 011 443 736 176557 5 No
RI 012 442 538 36349 5 No
RI 013 571 1266 5897 7 No
RI 014 824 626 1167770 6 No
RI 015 494 1055 15703 16 No
RI 016 730 1310 97044 25 No
RI 017 255 988 52835 25 No
RI 018 316 376 57154 8 No
Median 479 855 62,783 5.7
#, cells/ml;
&, HIV RNA copies per ml plasma (log10);
*, months; ART, antiretroviral therapy.
doi:10.1371/journal.pone.0032964.t002
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Fluorochrome-conjugated Abs used for polychromatic flow
cytometry analysis were CD3-Pacific Blue (UCHT1), CD3-PE/
Cy7 (SK7) CD4-Alexa700 (RPA-T4), CD8 APC-Cy7 (SKI),
CCR4-PE/Cy7 (1G1), CXCR3-PE/Cy5 (1C6), CD154-PE/Cy5
(89-76), CCR5-PE (2D7) b7-PE/Cy5 (FIB504), CCR6-PE (11A9)
and IFN-c-Alexa700 (B27) (BD Biosciences); CXCR3-FITC
(49801) (R&D Systems); b7-PE (FIB504) and IL-17A-PE (ebio64-
DEC17) and TNF-a-Pacific Blue (MAB11) (eBioscience). The b7
chain may associate with the a4 chain to form the a4b7 integrin or
with the aE chain to form the aEb7 integrin. In previous studies,
we demonstrated that the majority of peripheral blood T cells
expressed a4 but not the aE chain [48]. Based on this evidence, we
can assume the antibody against the b7 chain used in our study
identifies the a4b7 dimer.
For extracellular staining, PBMCs were washed with FACS
buffer (PBS 1X, 10% FBS (v/v) (Sigma), 0.02% sodium azide
(weight/volume)), stained with specific antibodies for 20 minutes
at 4uC, washed with FACS buffer, and fixed with a 2%
paraformaldehyde buffer. For cell phenotype analysis of antigen-
specific T-cells by flow cytometry, 200–5,000 events were acquired
using a BD LSRII flow cytometer. A viability stain (Vivid,
Invitrogen) was included in the specific staining cocktails to
exclude dead cells from our analysis. Results were analyzed using
the BD Diva software. Prior to use, all Abs were titrated for an
optimal signal to noise ratio. All Abs cocktails were validated
by comparing single to multiple staining, and gates were
established using fluorescence minus one (FMO), as previously
described [44].
HIV-1 peptide pool preparation
Stimulatory peptides were 15-mers with 11 amino acid overlaps
corresponding to HIV-1 clade B consensus Gag (n=123), Nef
(n=49), and Pol (n=249) (National Institute of Health (NIH)
AIDS Research and Reference Reagent Program, Germantown,
MD). Each peptide was diluted in DMSO at 12.5–50 mg peptide/
ml, depending on the peptide solubility and stored at 280uC.
These were used for the preparation of peptide pools (50–100 mg
peptide/ml), containing 11 to 28 peptides per pool, as described in
Table 4 and Table S1. Pools equivalent to the complete sequence
of Nef (100 mg peptide/ml), Gag (100 mg peptide/ml), and Pol
(50 mg peptide/ml) proteins were also prepared. Peptide pools
were stored at 280uC and used for CD154 assays (10 mg peptide/
ml) and proliferation assays (500 ng peptide/ml)
Candida albicans hyphaes culture and lysis
Candida albicans hyphaes was used a s positive control for the
induction of IL-17 production by T-cells (Figure S1), as previously
described [51]. Candida albicans LAM-1 strain was provided by Dr.
Louis de Repentigny (University of Montreal, Montreal, Quebec,
Canada), as colonies in a Petri dish. From the isolated colonies, the
yeast form was cultured overnight at 37uC in Yeast Peptone
Dextrose (YPD) medium (BD Bioscience). To induce the transition
from the yeasts form to hyphaes, 0.1–0.5610
6 yeasts/ml were
cultured in YPD media 20% FBS and incubated for 4 hours at
37uC. The hyphaes generated were washed and resuspended at
2610
6 cellules/100 ml in PBS (GIBCO). Micro glass-beads
(SIGMA) were added, and cell lysis was performed using the
FastPrep FP120 instrument (Thermo Savant, Carlsbad, CA). Cells
Table 3. Clinical parameters of chronically HIV-infected subjects under long-term viral suppressive ART (CI on ART).
Subjects CD4 counts
# CD8 counts
# Plasma viral load
& Time since infection* ART
CI 001 890 673 ,50 57 Yes
CI 002 463 757 ,50 152 Yes
CI 003 602 767 ,50 158 Yes
CI 004 563 613 ,50 86 Yes
CI 005 424 461 ,50 84 Yes
CI 006 731 413 ,50 51 Yes
CI 007 834 527 ,50 38 Yes
CI 008 552 715 ,50 139 Yes
CI 009 671 1120 ,50 242 Yes
CI 010 510 765 ,50 61 Yes
CI 011 799 1727 ,50 62 Yes
CI 012 501 278 ,50 90 Yes
CI 013 344 642 ,50 59 Yes
CI 014 604 1281 ,50 53 Yes
CI 015 443 322 ,50 18 Yes
CI 016 599 923 ,50 86 Yes
CI 017 688 1273 ,50 100 Yes
CI 018 434 583 ,50 165 Yes
CI 019 492 582 ,50 170 Yes
CI 020 529 690 ,50 49 Yes
Median 558 682 ,50 85
#, cells/ml;
&, HIV RNA copies per ml plasma (log10);
*, months; ART, antiretroviral therapy.
doi:10.1371/journal.pone.0032964.t003
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and then placed on ice for 2 minutes; this step was repeated 10
times. Lysates were stored frozen at 220uC. Proliferation assays
were performed to determine the optimal immunogenic concen-
trations of Candida albicans hyphae.
CD154/CD40L assay
To identify antigen-specific CD4
+ T-cells, the CD154/CD40L
assay was performed as previously described (89). Briefly, PBMC
from HIV-infected subjects were resuspended in RPMI 1640
(GIBCO), 100 units/ml Penicillin (GIBCO), 100 mg/ml Strepto-
mycin (GIBCO), and 2 mM of L-glutamine (RPMI) with 10%
FBS (SIGMA) at 10610
6 cells/ml. Cell suspension (200 ml/well)
were plated into 96-well plates and stimulated with 1 mg/ml
Staphylococcal enterotoxin B (SEB) (Toxin Technology), 5 mg/ml of
Cytomegalovirus (CMV) pp65 peptide pool (Miltenyi), 5 mg/ml
recombinant HIV-p24 protein (ImmunoDiagnostics, Inc.), or
10 mg/ml of HIV peptide pools (NIAID AIDS Reagent Program)
in the presence of 20 ml/well of anti-CD154-PE/Cy5 Abs (BD
Biosciences) and 2 mM of monensin (SIGMA) for 16 hrs at 37uC.
Cells were then harvested, stained for surface markers with
fluorescence-conjugated Abs against CD3, CD4, integrin b7,
CCR6, CXCR3, and CCR4, and analyzed by flow cytometry for
the expression of homing markers on CD3
+CD4
+CD154
+ T-cells.
CFSE dilution assay
To detect antigen-specific T-cell proliferation, the Carboxy
Fluoroscein Succinimidyl Ester (CFSE) dilution assay was
performed as previously described [52]. Briefly, PBMC were
loaded with 0.5 mM CFSE (Sigma) for 8 minutes at room
temperature. The optimal concentration for CFSE was deter-
mined by titration for each CFSE lot. Cells were then washed once
with PBS and once with RPMI 1640, and then cultured in 5 ml
polypropylene tubes (Becton Dickinson) at 2610
6 cells/ml in
RPMI with 10% human serum (Gemini). Cells were stimulated
with HIV peptide pools in which each peptide was at a
concentration of 500 ng/ml, 5 mg/ml recombinant HIV-p24
protein (ImmunoDiagnostics), 25 ng/ml SEB (Toxin Technolo-
gies) or 1 mg/ml pp65 CMV peptide pool (Miltenyi) for 6 days at
37uC. Cells were harvested, stained with fluorescence-conjugated
Abs against CD3, CD4, integrin b7, CCR6, CXCR3, CCR4,
and/or CCR5, and analyzed by flow cytometry for the phenotype
Table 4. Screening for HIV-1 specific CD4
+ and CD8
+ T-cells responses using the cell proliferation CFSE dilution assay.
% CFSE
low T-cells
Subjects SP 001 SP 006 SP 007 SP 011 SP 015
T-cells CD4
+ CD8
+ CD4
+ CD8
+ CD4
+ CD8
+ CD4
+ CD8
+ CD4
+ CD8
+
Medium
# 0.06 0.12 0.12 0.21 0.13 0.1 0.14 0.13 0.11 0.15
SEB 39.8
& 49.9 21.5 39.01 40.76 42.07 37.36 42.57 53.01 55.27
CMV pp65 1.05 2.3 0.36 3.9 57.69 8.94 2.32 3.71 25.58 25.99
HIV p24 -
# - - - 1.7 1.4 - - 0.74 1.17
Nef 5139–5187 0 . 2 3 0 . 5 7 ---2 . 8 7 -0 . 3 6 0 . 2 7 0.69
Nef 5139–5163 0 . 2 0 . 3 2 ---2 . 1 ---0.44
Nef 5164–5187 -0 . 3 4 ---0 . 5 2 ----
Gag 705–827 0.5 5.55 0.55 1.28 1.38 13.92 - 1.26 1.1 3.03
Gag 705–728 0.31 1.18 - - 0.29 0.5 - 1.14 - -
Gag 729–752 -----2 . 9 1 --0 . 2 8 -
Gag 753–776 0.21 2.29 - - 1.73 1.48 - - - -
Gag 777–800 0.24 2.33 - - 0.61 19.53 - 0.4 0.86 2.19
Gag 801–827 --------0 . 7 4 0.78
Pol 461–709 0.54 4.13 0.25 0.89 0.38 6.38 - 1.13 0.25 2.26
Pol 461–484 -----0 . 3 2 ----
Pol 485–508 0 . 1 9 -------0 . 4 5 0 . 4
Pol 509–532 ----------
Pol 533–556 0 . 2 2 0 . 2 3 ------0 . 2 9 4.75
Pol 557–580 -----3 . 8 9 ---0.38
Pol 581–604 ---------0 . 5
Pol 605–628 0.39 0.39 0.3 - - 0.29 - - - 1.28
Pol 629–652 0.45 0.47 - - 3.79 0.24 - - - 0.73
Pol 653–674 0 . 5 4 0 . 4 7 ---0 . 2 1 ---0.31
Pol 675–698 0.44 2.58 0.24 - - 0.22 - - 0.32 0.89
Pol 699–709 0 . 4 2 0 . 3 7 --------
Nef Gag Pol 1.87 9.21 0.34 1.01 1.47 14.05 0.56 1.92 0.82 3.65
#, background proliferation;
&, T-cell proliferation was considered positive when the % of CFSE
low T-cells in antigen-stimulated compared to the background was .2-fold higher.
doi:10.1371/journal.pone.0032964.t004
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+CD4
+CFSE
low and CD3
+CD4
2CFSE
low cells. In prelim-
inary experiments, we demonstrated that the majority (.95%) of
CD3
+CD4
2 cells were CD8
+ T-cells. When indicated, a viability
stain (Vivid; Invitrogen) was included in staining cocktails to
exclude dead cells from analysis.
Intracellular staining for cytokines
CFSE loaded PBMC were stimulated with antigen for 5 days
and then restimulated with 50 ng/ml PMA (SIGMA) and 1 mg/ml
Ionomycin (SIGMA) in the presence of 10 mg/ml Brefeldin A
(SIGMA) for 18 hours. The production of IFN-c, TNF-a, and IL-
17A was measured by intracellular staining with appropriate Abs
using the BD Cytofix/Cytoperm kit (BD Biosciences) according to
the manufacturer’s protocol.
Statistics
The significance of differences observed between-groups was
assessed using Mann-Whitney tests (for unpaired samples) and
Paired t-test (for paired samples) as specified in figure legends. The
correlation between study variables was assessed using a Spearman
correlation test and linear regression models. All statistical analyses
were performed using the GraphPad Prism 5 software. P-values
,0.05 were considered significant.
Results
Decreased frequency of CCR6-expressing CD8
+ and
CD4
+ T-cells in the peripheral blood of HIV-infected
subjects with slow and rapid disease progression: We
previously identified CCR6 as a marker for memory CD4
+ T-cells
being highly permissive to HIV infection in vitro and major sites for
HIV-DNA integration in infected subjects [44,48]. As a conse-
quence, the frequency of circulating CCR6
+CD4
+ T-cells is
dramatically reduced from the early stages of HIV infection and
the normalization of this frequency is not observed under viral
suppressive ART [44]. Considering the antiviral properties of
CD8
+ T-cells [19,53], we hypothesized that a robust control of
HIV disease progression is dependent on the ability of CD8
+ T-
cells to co-localize with CCR6-expressing CD4
+ T-cells. To test
this hypothesis, the expression of CCR6 was first quantified on
peripheral blood CD8
+ and CD4
+ T-cells from HIV-infected
subjects with slow and rapid disease progression. The cohort of
slow progressors (SP; n=14) included HIV-infected subjects with a
median time since infection of 16 years, median CD4 counts of
670 cells/ml, median CD4 counts of 831 cells/ml, and undetectable
or low plasma viral loads (median: 964 HIV RNA copies/ml) in
the absence of antiretroviral therapy (ART) (Table 1). The cohort
of HIV-infected progressors included recently infected untreated
(RI; n=18; median CD4 counts: 479 cells/ml; median CD8
counts: 855 cells/ml; median plasma viral load: 62,783 HIV RNA
copies/ml; median time since infection: 5.7 months) (Table 2) and
chronically infected under long-term (.1-year) viral-suppressive
ART (CI on ART; n=20; median CD4 counts: 558 cells/ml;
median CD8 counts: 682 cells/ml; median plasma viral load: ,50
HIV RNA copies/ml; median time since infection: 85 months)
subjects (Table 3). The frequency of CCR6-expressing CD8
+ and
CD4
+ T-cells and the CD8/CD4 ratios within total and CCR6
+
T-cell fractions were compared between HIV-uninfected and the
three groups of HIV-infected subjects.
The frequency of CCR6-expressing CD8
+ and CD4
+ T-cells
was significantly decreased in RI and CI on ART subjects
compared to uninfected controls; unexpectedly, this frequency was
also significantly decreased in SP compared to uninfected controls
and CI on ART subjects (Figure 1A–B). The CD8/CD4 ratios
within the total T-cell population were significantly higher in RI
(median: 1.4), CI on ART (median: 1.4), and SP subjects (median:
2.3) compared to uninfected controls (median: 0.9) and also in SP
compared to CI on ART subjects (Figure 1C). This suggests the
potential recruitment of excess CD8
+ T-cells in the vicinity of
CD4
+ T-cells. In contrast, the median CD8/CD4 ratios within the
CCR6
+ fraction were ,1 in HIV-infected and uninfected subjects,
with no significant differences between RI, CI on ART, and SP
subjects (Figure 1D). No significant correlations were found
between CD4 counts or plasma viral loads and all four parameters
investigated in Figure 1 within the three HIV-infected groups (data
not shown). These results demonstrate an alteration in the
frequency of CCR6-expressing CD8
+ and CD4
+ T-cells in HIV-
infected subjects regardless of their clinical characteristics of
disease progression. These results suggest the inability of CD8
+ T-
cells to be recruited in excess in the proximity of CCR6
+CD4
+ T-
cells, and this even in subjects with slow disease progression.
CD4
+ T-cells specific for HIV versus CMV preferen-
tially express gut-homing markers: HIV preferentially
infects HIV-specific CD4
+ T-cells, while CMV-specific CD4
+ T-
cells are relatively resistant to infection in vivo [41,49,54]. This
coincides with the fact that HIV-specific CD4
+ T-cells express
higher levels of the HIV CCR5 coreceptor and produce lower
levels of CCR5 binding chemokines than do CMV-specific CD4
+
T-cells [41,49,54]. We hypothesized that differences in viral
permissiveness between HIV-specific versus CMV-specific CD4
+
T-cells are also related to their distinct ability to home into
anatomic sites of active viral replication, such as the GALT. To
test this hypothesis, we investigated the gut-homing potential on
CD4
+ T-cells specific for HIV versus CMV. The SEB superantigen
is known to induce polyclonal T-cell activation [52] and was used
as a positive control. The tissue-specific homing molecules studied
were integrin b7 for the migration across the GALT endothelium
[30,39,46], CCR6 for the migration into the GALT Peyer’s
Patches [33,55], CXCR3 for the migration into inflammatory
sites, including the GALT [30,39,46,56], and CCR4 for the
migration into the skin [57]. Experiments were performed with
PBMC from seven HIV-infected treatment-naı ¨ve subjects with
slow disease progression (Table 1), because they exhibited
relatively high frequencies of HIV-specific CD4
+ and CD8
+ T-
cells (Table 4 and Table S1). This choice is also justified by the fact
that the frequency of CD4
+ and CD8
+ T-cells expressing CCR6 is
also altered in the peripheral blood of SP subjects compared to
uninfected controls (Figure 1).
In a first experimental approach, antigen-specific CD4
+ T-cells
were identified based on their expression of CD154 (CD40 ligand,
CD40L) using flow cytometry analysis (Figure S1A), as previously
described by others [58]. The PBMCs from HIV-infected
individuals were screened for the ability to respond to an antigen
panel that included HIV Nef (n=3), Gag (n=6) and Pol (n=11)
overlapping peptide pools, HIV-p24 recombinant protein, SEB,
and CMV-pp65 recombinant protein (Table S1). The PBMCs
were then stimulated with the most immunogenic antigenic panel
and the expression of integrin b7, CCR6, CXCR3, and CCR4
was analyzed on antigen-specific CD154
+CD4
+ T-cells by
polychromatic flow cytometry (Figure S1A–B). The phenotype of
CD154
+CD4
+ T-cells specific for different HIV peptide pools was
highly heterogeneous within the same donor. Also, inter-donor
variations were observed in the expression of homing molecules on
CD154
+CD4
+ T-cells, even those specific for the same HIV
peptide pool (Figure S1C). Regardless of this heterogeneity,
statistical analysis of homing molecule expression demonstrated
that HIV-specific compared to CMV-specific CD154
+CD4
+ T-
cells expressed significantly higher levels of the integrin b7 (Figure
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displayed increased expression of the integrin b7, CCR6, CXCR3,
and CCR4 (Figure S1D). These results demonstrate that HIV-
specific CD154
+CD4
+ T-cells distinguish from cells of other
antigenic specificities (CMV, SEB) by their high expression of both
gut-homing markers integrin b7 and CCR6.
In a second experimental approach, antigen-specific CD4
+ T-
cells were identified based on their proliferation potential (CFSE
low
phenotype) using the CFSE dilution assay (Figure 2A), as
previously described [52]. The PBMCs from HIV-infected
individuals were screened for the ability to respond to an antigen
panel that included HIV Nef (n=3), Gag (n=6) and Pol (n=11)
overlapping peptide pools, HIV-p24 recombinant protein, SEB,
and CMV-pp65 recombinant protein (Table 4). The PBMCs were
then stimulated with the most immunogenic antigenic panel and
the expression of integrin b7, CCR6, CXCR3, and CCR4 was
quantified on CFSE
low CD4
+ T-cells by polychromatic flow
cytometry (Figure 2B). Similar to data obtained on HIV-specific
CD154
+CD4
+ T-cells (Figure S1C), inter- and intra-donor
variations were observed in the phenotype of CFSE
low CD4
+ T-
cells specific for different HIV peptide pools (Figure 2C). CXCR3
was expressed by the majority of antigen-specific cells, while the
expression of integrin b7, CCR6 and CCR4 was limited to a
fraction of cells (Figure 2C). The CD4
+ T-cells proliferating in
response to the HIVNefGagPol peptide pool versus CMV from
matched donors expressed significantly higher levels of integrin b7,
CCR6, and CXCR3, with not significant differences regarding
CCR4 expression (Figure 2D). The same trend was observed when
CD4
+ T-cells specific for all HIV peptide pools were compared
with those specific for CMV from five different donors (Figure
S2A). The HIV-specific CD4
+ T-cells identified as CD154
+ versus
CFSE
low cells differed in the expression of homing receptors; these
differences were observed when cells were stimulated with distinct
(Nef versus Gag, respectively) or the same HIV antigenic pools
(HIV-p24) (Figure S1C and Figure 2C). However, the expression
at high levels of both integrin b7 and CCR6 remained a unique
feature of HIV-specific CD4
+ T-cells when compared to CMV-
specific cells (Figures S1D and S2A, and Figure 2D). This unique
particularity of HIV-specific CD4
+ T-cells may confer them the
ability to migrate into the GALT, a major site of HIV replication
in vivo [8,59].
CCR6 is a well established marker for Th17 and Th1Th17 cells
with a CCR4
+CCR6
+ and CXCR3
+CCR6
+ phenotype [60]. Our
results demonstrated that only a minority of CFSE
low HIV-specific
Figure 1. The frequency of CD8
+ and CD4
+ T-cells expressing CCR6 is decreased in HIV infected subjects with slow and rapid
disease progression. Peripheral blood mononuclear cells (PBMC) from HIV-uninfected (HIV-; n=13) and HIV+ subjects recently infected untreated
(RI, n=18), chronically infected under long-term viral suppressive antiretroviral therapy (CI on ART; n=20), and slow progressors (SP, n=14) were
stained with a cocktail of fluorescence-conjugated CD3, CD4, and CCR6 Abs. The frequency of (A) CD3
+CD4
2 T-cells (referred to as CD8
+ T-cells) and
(B) CD3
+CD4
+ T-cells (referred to as CD4
+ T-cells) expressing CCR6 was quantified by polychromatic flow cytometry and compared between HIV-
uninfected controls and RI, CI on ART, and SP HIV-infected subjects. The CD8/CD4 T-cell ratios were calculated within the total (C) and CCR6
+ T-cell
fractions (D) in the group of HIV-uninfected controls and the three groups of HIV-infected subjects. Horizontal bars indicate median values. Mann-
Whitney p-values are indicated in the figures.
doi:10.1371/journal.pone.0032964.g001
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+ T-cells produced IL-17, while a larger fraction produced
IFN-c and TNF-a (Figure S3). These results indicate that HIV-
specific CD4
+ T-cells exhibit a Th1Th17 polarization profile. We
previously demonstrated that a Th1Th17 profile is favorable to
active HIV replication in vitro [44]. Therefore, HIV-specific cells
from SP subjects may be highly permissive to HIV, as previously
demonstrated in HIV progressors [41,49,54].
The colocalization potential of HIV-specific CD4
+ and
CD8
+ T-cells is mediated by the integrin b7 but not
CCR6: The antiviral properties of CD8
+ T-cells are well
characterized [19,20,21] and depend on their ability to colocalize
in excess with target cells, such as CD4
+ T-cells [28,29]. We next
investigated the expression of gut-homing molecules on HIV-
specific CD8
+ T-cells in order to evaluate their ability to colocalize
with HIV-specific CD4
+ T-cells for an efficient control of HIV
replication in vivo. In preliminary experiments, we demonstrated
that the majority of CD8
+ T-cells exhibited a CD3
+CD4
2
phenotype (data not shown). Antigen-specific CD8
+ T-cells were
identified as CFSE
low cells (Figure 3A) and tested for their
expression of the integrin b7, CCR6, CXCR3, and CCR4
(Figure 3B). Similar to antigen-specific CD4
+ T-cells (Figure 2C),
the expression of the homing receptors on CFSE
low CD8
+ T-cells
was subject to inter-donor variations (Figure 3C). Despite this
heterogeneity, HIVNefGagPol-specific versus CMV-specific CFSE
low
CD8
+ T-cells from matched donors expressed significantly higher
levels of integrin b7, while no significant differences were observed
in the levels of CCR6, CXCR3, and CCR4 expression (Figure 3D).
The same results were observed when CD8
+ T-cells specific for all
HIV peptide pools were compared with those specific for CMV
(Figure S2B). These results suggest an increased ability of HIV-
specific versus CMV-specific CD8
+ T-cells to migrate via integrin
b7 into the GALT, which is likely a site for the initial priming of
HIV-specific T-cells.
To further investigate the colocalization potential of HIV-
specific CD4
+ and CD8
+ T-cells, the frequency of cells expressing
gut-homing molecules was compared between matched CD4
+ and
CD8
+ T-cells proliferating in response to specific HIV peptide
pools. Results depicted in Figure 4A show that HIV-specific CD8
+
compared to CD4
+ T-cells express significantly higher levels of
integrin b7, lower levels of CCR6 and CCR4, and similarly high
levels of CXCR3. Spearman correlation and linear regression
models were applied and demonstrated a positive correlation
between the frequency of HIV-specific CD4
+ and CD8
+ T-cells
expressing the integrin b7 and CXCR3; this correlation was not
observed for CCR6 and CCR4 (Figure 4B). Moreover, there was a
positive correlation between the frequency of HIV-specific CD4
+
and CD8
+ T-cells co-expressing the integrin b7 and CXCR3
(Figure 4C). Furthermore, the b7
+CXCR3
+ phenotype appears to
be a unique feature of HIV-specific T-cells since the frequency of
b7
+CXCR3
+ cells was significantly higher in HIVNefGagPol-specific
versus CMV-specific CD4
+ and CD8
+ T-cells from four matched
SP subjects (Figure S2C). The proliferation of CD8
+ compared to
CD4
+ T-cells in response to a specific HIV peptide pool was
significantly higher in all five HIV-infected subjects (Figure 4D),
with median CD8/CD4 ratios of 3.2, 2.3, 4.1, 5.6, and 2.8 in SP
subjects 001, 006, 007, 011, and 015, respectively (data not
shown). These results suggest that a significant fraction of HIV-
specific CD8
+ T-cells may colocalize with CD4
+ T-cells (at high
CD8/CD4 ratios) in certain anatomic sites of the GALT where
homing depends on integrin b7 and CXCR3. In contrast, HIV-
specific CD8
+ T-cells express low levels of CCR6 and CCR4 and
thus may be impaired in their ability to colocalize and control viral
replication in CCR6
+CCR4
+ CD4
+ T-cells, such as Th17 cells
[51] which are highly permissive to infection [44,45]. Thus, the
low expression of CCR6 on CD8
+ T-cells may reflect their limited
ability to control HIV replication in CD4
+ T-cells from certain
GALT sites such as the Peyer’s Patches, where homing depends on
CCR6 [32,33,34].
The retinoic acid pathway regulates expression of
integrin b7 but not CCR6 and CCR5 on HIV-specific T-
cells: The imprinting for gut-homing is regulated at least in part
by RA, a derivate of vitamin A metabolism produced by the
intestinal dendritic cells [46,47]. Of note, exposure of CD4
+ T-
cells to RA upregulates integrin b7 and CCR5 expression and
renders them highly permissive to HIV replication [61,62]. Here,
we investigated whether RA can be used to manipulate the
colocalization potential of HIV-specific CD4
+ and CD8
+ T-cells
via integrin b7 and CCR6. With this in mind, PBMC from SP
subjects were exposed to the HIVNefGagPol peptide pool, SEB, or
CMV in the presence or absence of all-trans RA (ATRA) or the
RA antagonist LE540. In preliminary experiments, we demon-
strated that at physiological dose (10 nM [61,63]), ATRA did not
have any significant effect on cell proliferation, while LE540 at
1 mg/ml [64] decreased integrin b7 expression on SEB-specific T-
cells without interfering with cell viability (data not shown). The
expression of integrin b7, CCR5, and CCR6 was quantified on
CFSE
low T-cells by multicolor flow cytometry. Exposure to ATRA
and LE540 led to a significant increase and decrease, respectively,
in the integrin b7 expression on CD4
+ T-cells specific for HIV-,
SEB, and CMV and also on CD8
+ T-cells specific for HIV and
SEB (Figure 5A). The ATRA also increased expression of CCR5
on SEB-specific and CMV-specific but not on HIV-specific T-cells
(Figure 5B), where levels of CCR5 expression were higher,
although not statistically significant due to donor-to-donor
variability, compared to those on SEB-specific and CMV-specific
T-cells (Paired t-Test p=0.04 and p=0.1, respectively). In
contrast, ATRA and LE540 treatment did not interfere with the
expression of CCR6 on antigen-specific CD4
+ or CD8
+ T-cells
(Figure 5C). These results demonstrate that the RA pathway
regulates the expression of integrin b7 but does not interfere with
CCR5 and CCR6 expression on HIV-specific CD4
+ and CD8
+ T-
cells.
To gain more insights into the regulation of trafficking potential
of HIV-specific T-cells, we studied the effects of RA and LE540 on
the frequency of HIV-specific T-cells with a b7
+CCR5
+ and
b7
+CCR6
+ phenotype. The CD4
+ and CD8
+ T-cells proliferating
Figure 2. Preferential gut-homing potential of HIV-specific versus CMV-specific CD4
+ T-cells. PBMC from SP subjects were loaded in CFSE
(0.5 mM) and stimulated with different HIV Nef, Gag, Pol peptide pools (500 ng/ml), recombinant HIV-p24 (5 mg/ml), SEB (25 ng/ml), or the
recombinant CMV-pp65 peptide pool (1 mg/ml) for 6 days at 37uC. Antigen-specific T-cells were identified as CFSE
low cells, as previously described
[52]. Cells were stained with a cocktail of fluorescence-conjugated CD3, CD4, integrin b7, CCR6, CXCR3, and CCR4 Abs and analyzed by polychromatic
flow cytometry for (A) the frequency of CFSE
lowCD3
+CD4
+ T-cells (referred to as CD4
+ T-cells) and (B–D) the expression of integrin b7, CCR6, CXCR3,
and CCR4 on antigen-specific CFSE
lowCD4
+ T-cells. (A–B) Shown are results from one donor (i.e., SP 007) generated upon stimulation of PBMC with
HIV Gag705–827 peptide pool, representative of results generated with cells from five different donors. (C) Shown is the expression of the homing
receptors on CFSE
lowCD4
+ T-cells specific for SEB, CMV and different HIV peptide pools in five different SP subjects. (D) Shown is the homing
molecule expression on matched CFSE
lowCD4
+ T-cells specific for CMV versus HIVNefGagPol peptide pool in four-five different SP subjects. Paired T-test
p-values are indicated in the figures.
doi:10.1371/journal.pone.0032964.g002
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PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e32964Figure 3. Homing potential of CD8
+ T-cells proliferating in response to HIV peptides. PBMC from five SP subjects were stimulated and
stained with Abs as in Figure 2. At day 6 of stimulation, cells were analyzed by polychromatic flow cytometry for (A) the frequency of
CFSE
lowCD3
+CD4
2 T-cells (referred to as CD8
+ T-cells) and (B–D) the expression of b7 integrin, CCR6, CXCR3, and CCR4 on CFSE
lowCD8
+ T-cells. (A–B)
Shown are results from one donor (i.e., SP 007) generated upon stimulation with HIV Gag705–827 peptide pool. (C) Shown is the expression of the
homing receptors on CFSE
lowCD8
+ T-cells specific for SEB, CMV, and different HIV peptide pools in five different SP subjects. (D) Shown is the homing
molecule expression on matched CFSE
lowCD8
+ T-cells specific for CMV versus HIVNefGagPol peptide pool in five different SP subjects. Paired T-test p-
values are indicated in the figures.
doi:10.1371/journal.pone.0032964.g003
Figure 4. Potential colocalisation of HIV-specific CD8
+ and CD4
+ T-cells via integrin b7 but not CCR6. (A–C) PBMC from five SP subjects
were stimulated with different HIV peptide pools or recombinant HIV-p24 and analyzed by polychromatic flow cytometry for the expression of
homing molecules, as described in Figures 2 and 3. HIV-specific CD4
+ and CD8
+ T-cells were analyzed for (A–C) the expression of the homing
molecules b7 integrin, CCR6, CXCR3, and CCR4 (D) the proliferation potential. (A) Shown is the expression of homing molecules on matched CD4
+
versus CD8
+ T-cells specific for different HIV peptide pools in five different SP subjects. Shown are correlations between (B) the frequency of matched
HIV-specific CD4
+ and CD8
+ T-cells expressing b7 integrin, CCR6, CXCR3, or CCR4 alone, and (C) co-expressing the b7 integrin and CXCR3 molecules
(b7
+CXCR3
+ phenotype). (D) Shown is the percentage of matched CD4
+ versus CD8
+ T-cells proliferating (CFSE
low) in response to different HIV
peptide pools. Paired T-test p-values are indicated in the Figures A and D. Spearman correlation r and p-values and linear regression r
2 values are
indicated in the Figures B and C.
doi:10.1371/journal.pone.0032964.g004
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PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e32964Figure 5. Retinoic acid activation pathway regulates integrin b7 expression on HIV-specific T-cells. PBMC from SP subjects were loaded
in CFSE (0.5 mM) and stimulated with HIVNef-Gag-Pol peptide pool (500 ng/ml), SEB (25 ng/ml), or the recombinant CMV-pp65 peptide pool (1 mg/ml)
for 6 days at 37uC in the presence or absence of all-trans-retinoic acid (ATRA; 10 nM) or the RA antagonist LE540 (1 mg/ml). Cells were stained with a
cocktail of fluorochrome-conjugated CD3, CD4, integrin b7, CCR5 or CCR6 Abs and analyzed for the expression of (A) integrin b7, (B) CCR5, and (C)
CCR6 on CFSE
low CD4
+ and CD8
+ T-cells specific for SEB, CMV, and HIV antigens. Experiments were performed with cells from four SP subjects
(mean6SD). Paired t-Test p-values are indicated in the figures.
doi:10.1371/journal.pone.0032964.g005
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an increased frequency of b7
+CCR5
+ T-cells (Figure 6A and C).
The pool of HIV-specific CD4
+ T-cells included higher frequen-
cies of cells with a b7
+CCR6
+ phenotype compared to cells specific
for CMV or SEB, while CD8
+ T-cells specific for HIV, CMV, or
SEB included very low frequencies of b7
+CCR6
+ T-cells
(Figure 6B). Exposure to ATRA and LE540 led to a significant
increase and decrease, respectively, in the frequency of HIV-
specific CD4
+ and CD8
+ T-cells with a b7
+CCR5
+ phenotype
(Figure 6D). Since ATRA does not modulate CCR5 expression on
HIV-specific cells (Figure 5C), the increase in the frequency of
b7
+CCR5
+ cells (Figure 6D) is likely due to the upregulation of
integrin b7 expression on existing CCR5
+ T-cells. Finally, ATRA
and LE540 treatment had no significant effects on the frequencies
of HIV-specific CD4
+ or CD8
+ T-cells with a b7
+CCR6
+
phenotype (Figure 6E). These results provide evidence that ATRA
may be used to enhance recruitment of HIV-specific CD4
+ and
CD8
+ T-cells across the intestinal endothelium via the integrin b7.
In contrast, ATRA does not interfere with CCR6 expression and
cannot facilitate the in situ colocalization of CD8
+ T-cells with
CCR6
+CD4
+ T-cells.
Discussion
The GALT is a major site for HIV replication in vivo [8,59],
with HIV-specific CD4
+ T-cells being highly permissive to
infection [49]. The recruitment of effector CD8
+ T-cells in the
proximity of target CD4
+ T-cells is a prerequisite for an efficient
control of viral replication in vivo [29,65]. In this study, we
investigated the potential of HIV-specific CD8
+ T-cells to
colocalize in excess with CD4
+ T-cells in the GALT and explored
the role of the retinoic acid (RA) activation pathway in regulating
this process. We demonstrated that a large fraction of HIV-specific
CD4
+ and CD8
+ T-cells express the gut-homing molecules
integrin b7 and CXCR3 while CCR6, a marker of HIV
permissiveness in CD4
+ T-cells [44,48], was expressed at high
and low levels on HIV-specific CD4
+ and CD8
+ T-cells,
respectively. We also demonstrated that RA upregulated integrin
b7 expression but did not affect CCR6 expression. Our data
support a model in which HIV-specific CCR6
+CD4
+ T-cells
escape the antiviral control of CD8
+ T-cells in certain GALT sites
(e.g., Peyer’s Patches) where migration is dependent on CCR6
[32,33,34] (Figure 7). Considering the critical role played by
CCR6
+ Th17 cells in mucosal immunity [66], uncontrolled HIV
replication in these cells likely leads to dramatic alterations of
mucosal immunity and microbial translocation [13,59,67,68,69].
These observations were made in a cohort of SP subjects with a
median time since infection 16 years. Whether CD8
+ T-cells
colocalize in excess with CCR6
+CD4
+ T-cells for an efficient
control of HIV replication in SP subjects during the first years of
infection or in HIV-exposed uninfected individuals remains to be
determined.
Our initial hypothesis was that the colocalization potential of
CD8
+ T-cells with CCR6
+CD4
+ T-cells was altered in HIV-
infected subjects with disease progression but not in slow
progressors (SP). To test this hypothesis, the expression of CCR6
was quantified on peripheral blood CD8
+ and CD4
+ T-cells from
SP subjects and two other cohorts of HIV progressors, recently
infected untreated (RI) and chronically infected under viral
suppressive ART subjects (CI on ART). Unexpectedly, we found
an alteration in the frequency of CCR6-expressing CD8
+ and
CD4
+ T-cells in HIV-infected subjects regardless of their clinical
characteristics of disease progression. This suggested the inability
of CD8
+ T-cells to be recruited in excess in the proximity of
CCR6
+CD4
+ T-cells, and this even in subjects with slow disease
progression. This is consistent with studies reporting immunolog-
ical alterations related to HIV persistence in CD4
+ T-cells and
chronic immune activation in SP subjects, especially after many
years of infection in the absence of ART [23,24,70,71].
According to the paradigm of tissues-specific homing, effector
memory T-cells are imprinted with the ability to recirculate into
peripheral tissues where the initial antigen encounter took place
[37,46,56,72]. A specific combination of adhesion molecules and
chemokine receptors regulate the multi-step process of tissue-
specific homing of T-cells [73,74]. Also, local presentation of
antigens by endothelial cells contribute to the recruitment of T-
cells into specific sites [75]. In this study, we demonstrated that
HIV-specific CD154
+CD4
+ T-cells express molecules regulating
migration into the GALT (integrin b7, CCR6, CXCR3) and skin
(CCR4). Considering the fact that the GALT [59,69] but not the
skin are sites of HIV replication in vivo, this broad homing potential
of HIV-specific CD154
+CD4
+ T-cells was unexpected and
inconsistent with the paradigm of tissue-specific homing of
pathogen-specific T-cells. This exception from the rule is not
unique. In fact, T-cells induced upon subcutaneous yellow fever
immunization have a dynamic migration program and home into
multiple distal tissues, including the GALT [76].
CD154 was proposed as a surrogate marker for the identifica-
tion of cytokine-producing T-cells in response to an antigenic
stimulation [58]. However, we found a differential expression of
homing molecules on recently activated CD154
+ compared to
proliferating CD4
+ T-cells (CFSE
low) in response to HIV, SEB, or
CMV. The skin-homing receptor CCR4 was highly expressed on
CD154
+ compared to CFSE
low CD4
+ T-cells specific for HIV and
CMV. This is consistent with the paradigm that T-cells are
originally imprinted with a skin-homing potential that is lost
during the process of differentiation into specialized Ag-specific
cells [46]. Also, the expression of CCR6 was higher on CMV-
specific CD154
+ compared to CFSE
low CD4
+ T-cells, while the
integrin b7 expression was lower on SEB-specific CD154
+
compared to CFSE
low CD4
+ T-cells. The finding that some
antigens induced either CD154
+ or CFSE
low CD4
+ T-cells but not
both suggests that CD154 expression does not predict the ability of
a cell to proliferate. Accordingly, CD154
+CD4
+ T-cells were
mainly triggered by HIVNef peptide pools, while CFSE
lowCD4
+ T-
cells were selectively induced by HIVGag peptide pools (Table 4
and Table S1). Thus, HIV-specific CD154
+ and CFSE
low CD4
+
T-cells exhibit distinct homing potential and antigenic specificity
and therefore may represent different stages of CD4
+ T-cell
differentiation with distinct roles in antiviral immunity. The
molecular determinism underlying these differences remains
unclear but might be related to the anatomic site of original
antigenic priming.
The HIV establishes a persistent infection by mechanisms that
are not clearly understood, and viral eradication is not achieved
under current antiretroviral therapies [14,77]. The CD4
+ T-cells
play a critical role in HIV pathogenesis [77]. The HIV-specific
compared to CMV-specific CD4
+ T-cells are preferentially
infected with HIV in vivo [49]. This is because HIV-specific
CD4
+ T-cells express high levels of the HIV coreceptor CCR5
[41] and produce low levels of CCR5 binding chemokines and
therefore fail to protect themselves from infection in an autocrine
manner [54]. Consistent with the evidence that the GALT is a
major site of HIV replication [59,69], we observed that HIV-
specific compared to CMV-specific CD154
+CD4
+ T-cells ex-
pressed at high levels both gut-homing molecules integrin b7 and
CCR6. We also observed increased expression of integrin b7 and
CCR6 on CD4
+ T-cells proliferating in response to HIV
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homing, the integrin b7 was identified as a new HIV-gp120
binding receptor [61,62], and its expression on HIV-specific CD4
+
T-cells might favor HIV binding on these cells and viral
dissemination from the portal sites of entry. The CCR6 is a
marker for memory CD4
+ T-cells with a Th17 and Th1Th17
lineage polarization profile [51]. We found that a small fraction of
HIV-specific cells produced IL-17, with the majority of cells
producing IFN-c and TNF-a. Thus, HIV-specific CD4
+ T-cells
exhibit a Th1Th17 polarization profile. Indeed other studies
demonstrated that very few HIV-specific CD4
+ T-cells produce
IL-17 [78]. Considering our previous findings that HIV replicates
actively in T-cells with a Th1Th17 polarization profile [44], these
results suggest that HIV-specific CD4
+ T-cells in SP subjects are
also permissive to infection. Consistent with this prediction, the
expression of the HIV co-receptor CCR5 was relatively high on
HIV-specific CD4
+ T-cells from SP subjects. This may render
them extremely permissive to infection and may explain why some
of the SP subjects begin loosing their CD4 counts, especially after
many years of infection in the absence of ART [16]. Hence, the
expression of integrin b7, CCR6, and CCR5 represents a unique
‘‘signature’’ for HIV-specific T-cells. The relationship between
imprinting for gut-homing and viral permissiveness was recently
demonstrated for adenovirus serotype 5 (AD5)-specific CD4
+ T-
cells generated upon AD5-HIV vaccination (STEP trial), as cells
exhibited an integrin a4b7
+CCR5
+ phenotype and high suscep-
tibility to HIV infection [79]. The molecular mechanisms that
control homing potential of HIV-specific T-cells are likely related
to the cellular/tissue environment in which these cells initially
encountered antigen. Indeed, the GALT dendritic cells produce
RA, which is known to trigger integrin a4b7 expression and
upregulate CCR5 expression on T-cells [47,48,61]. Similarly, the
GALT environment is rich in Th17 polarizing cytokines (TGF-b,
IL-1, IL-6) [51,80,81] that may trigger CCR6 expression on HIV-
specific CD4
+ T-cells.
The CD8
+ T-cells control HIV replication in target cells via
cytotoxic and non-cytotoxic mechanisms [19,20,21]. Recent
studies using visualization techniques demonstrated that recruit-
ment of excess viral-specific effectors in the vicinity of target cells is
critical for the control of viral replication and disease progression
in an SIV model of infection [29]. Our results reveal that matched
HIV-specific CD8
+ and CD4
+ T-cells may colocalize to anatomic
sites where recruitment is mediated by integrin b7, CXCR3 and/
or CCR5 (Figure 7A). The expression of integrin b7 on both HIV-
specific CD8
+ and CD4
+ T-cells supports the idea that these cells
are primed with the antigen within the GALT, where they are
likely exposed to factors that imprint cells with a gut-homing
potential [46,47]. The CXCR3 is responsible for leukocyte
migration into the inflammatory sites, including the gut [56]. Of
note, a decreased frequency of CXCR3
+CD8
+ T-cells was
reported in advanced HIV-1 infection that might contribute to
cytotoxic T-lymphocyte dysfunction [82]. In our SP cohort, HIV-
specific T-cells expressed maximal levels of CXCR3, and this
suggests their functional competence in vivo. In contrast, we
observed that CCR6 was expressed at high levels on HIV-specific
CD4
+ but not CD8
+ T-cells. The low expression of CCR6 on
HIV-specific CD8
+ T-cells was consistent with the decreased
frequency of memory CCR6
+CD8
+ T-cells in the peripheral blood
Figure 6. Retinoic acid upregulates the frequency of HIV-specific T-cells with a b7
+CCR5
+ but not b7
+CCR6
+ phenotype. PBMC from SP
subjects were loaded in CFSE (0.5 mM) and stimulated as in Figure 5. Cells were stained with a cocktail of fluorochrome-conjugated CD3, CD4, and
integrin b7, and CCR5 or CCR6 Abs. CFSE
low CD4
+ and CD8
+ T-cells specific for SEB, CMV, and HIVNef-Gag-Pol peptide pool were analyzed for the co-
expression of (A) integrin b7 and CCR5 and (B) integrin b7 and CCR6. The effects of RA and LE540 on the frequency of Ag-specific CD4
+ and CD8
+ T-
cells exhibiting a b7
+CCR5
+ or b7
+CCR6
+ phenotype were then analyzed. (A–B) Shown are results from one representative SP subject and (C–E)
statistical analysis of results from experiments performed with cells from five SP subjects (mean6SD). Paired t-Test p-values are indicated in the
figures.
doi:10.1371/journal.pone.0032964.g006
Figure 7. Proposed model for the differential colocalization of HIV-specific CD4
+ and CD8
+ T-cells into the GALT. The control of viral
replication is dependent on the in situ colocalization of excess effector versus target cells [28]. Given the results included in Figures 1–6 of the present
manuscript, we propose a model where (A) HIV replication in CD4
+ T-cells may be controlled by CD8
+ T-cells in certain GALT sites (e.g., lamina
propria), where recruitment is dependent on integrin b7, CXCR3 and CCR5 because of an increased ratio between HIV-specific CD8
+ and CD4
+ T-cells.
In contrast, (B) HIV-specific CD4
+ T-cells recruited into other GALT sites via CCR6 (e.g., Peyers’s Patches) may escape the CD8
+ T-cell-mediated antiviral
control due to a limited CCR6-dependent colocalization potential of CD4
+ and CD8
+ T-cells. This model is in line with our previous findings that
CCR6
+CD4
+ T-cells harbor the highest levels of integrated HIV-DNA in vivo [44] and suggests that novel therapeutic strategies aimed at increasing
CCR6 expression on CD8
+ T-cells may lead to a better control of HIV replication in CCR6
+CD4
+ T-cells.
doi:10.1371/journal.pone.0032964.g007
HIV-Specific CD8+ and CD4+ T-Cell Colocalization
PLoS ONE | www.plosone.org 15 March 2012 | Volume 7 | Issue 3 | e32964of HIV-infected subjects with slow and rapid disease progression
compared to uninfected individuals. This points to the fact
that regardless of the clinical characteristics of HIV disease
progression, CD8
+ T-cells have a limited ability to colocalize with
CCR6
+CD4
+ T-cells and therefore to control HIV replication in
these cells. This may explain in part why CCR6
+CD4
+ T-cells are
highly permissive to HIV-DNA integration in vivo [44]. The escape
of CCR6
+CD4
+ T-cells from the non-cytotoxic antiviral control by
CD8
+ T-cells may also explain the preferential depletion of these
cells during disease progression [44], likely via a virus-induced
toxicity mechanism [83].
Several previous studies demonstrated that HIV-specific CD8
+
T cells from SP subjects are efficient in controlling viral replication
ex vivo [15,16,19]. This is consistent with our observations in vitro
that HIV replication in antigen-stimulated PBMC from the seven
SP subjects was controlled (undetectable HIV-p24 levels, as
quantified by ELISA), likely by CD8
+ T-cells (Ancuta, unpub-
lished observations). However, the situation in vivo may be
different. Our results support a model in which the low expression
of CCR6 on HIV-specific CD8
+ T-cells is exploited by HIV-1 for
its efficient replication in CCR6
+CD4
+ T-cells in some GALT sites
such as the Peyer’s Patches (Figure 7B). In this context, it is of
interest to identify ways to increase the ability of HIV-specific
CD8
+ T-cell to colocalize with HIV-specific CD4
+ T-cells. We
found that RA increased the expression of integrin b7 on T-cells
specific for HIV, CMV and SEB and the frequency of T-cells
specific for CMV and SEB with a b7
+CCR5
+ phenotype. The
HIV-specific CD4
+ and CD8
+ T-cells included a relatively high
fractions of b7
+CCR5
+, and their frequency remained high upon
RA treatment. In contrast, HIV-specific CD4
+ compared to CD8
+
T-cells included an increased frequency of cells with a b7
+CCR6
+
phenotype and the physiological dose of RA used (10 nM, [61,63])
did not upregulate CCR6 expression on CD8
+ nor CD4
+ T-cells.
Other factors responsible for Th17 differentiation, such as TGF-b,
IL-1, IL-6 [51,80,81], might be involved in regulating CCR6
expression on HIV-specific CD8
+ T-cells and remain to be
identified.
Together, these results suggest the ability of HIV-specific CD8
+
and CD4
+ T-cells to colocalize into the GALT (e.g., lamina
propria) via integrin b7, CCR5, and CXCR3 and reveal a limited
potential of HIV-specific CD8
+ T-cells to migrate into other
GALT sites (e.g., Peyer’s Patches), where recruitment is dependent
on CCR6 [32,33,34]. Studies on gut biopsies are required to
validate our proposed model (Figure 7), which is consistent with
the preferential permissiveness of CCR6
+CD4
+ T-cells to HIV
infection in vivo [44]. In this context, understanding molecular
mechanisms regulating CCR6 expression on HIV-specific CD8
+
T-cells, together with the expression of the CCR6 ligands into the
GALT, is of paramount importance for the design of new
therapeutic strategies aimed at HIV eradication. However, caution
must be taken when designing such strategies to avoid an increased
recruitment of HIV targets at the portal sites of mucosal entry.
Finally, studies evaluating the functionality of the immune system
in response to ART and vaccination may gain in physiological
relevance if they consider monitoring the in situ colocalization
potential of HIV-specific CD8
+ and CD4
+ T-cells as a new
correlate of protection.
Supporting Information
Figure S1 The HIV-specific versus CMV-specific
CD154
+CD4
+ T-cells preferentially express a gut-homing
potential. PBMC from SP subjects were stimulated with different
HIV Nef, Gag, Pol peptide pools (10 mg/ml), recombinant HIV-
p24 protein (5 mg/ml), SEB (1 mg/ml), or CMV-pp65 peptide pool
(5 mg/ml) for 18 hours at 37uC in the presence of fluorescence
conjugated anti-CD154-PE/Cy5 Abs (20 ml/2610
6 cells/0.2 ml/
well). Antigen-specific T-cells were identified as CD154
+ cells, as
previously described [58]. Cells were harvested, stained with a
cocktail of fluorochrome-conjugated CD3, CD4, and b7 integrin,
CCR6, CXCR3, or CCR4 Abs and analyzed by polychromatic
flow cytometry for (A) the expression of CD154 on CD3
+CD4
+ T-
cells and (B–D) the expression of homing molecules on
CD3
+CD4
+CD154
+ T-cells. (A–B) Shown are results from one
SP subjects (SP 015 stimulated with the HIV Nef5164-5187 peptide
pool), representative of results generated with cells from five
different donors. (C) The expression (%) of homing receptors was
analyzed on CD154
+ T-cells specific for SEB, CMV, and different
HIV peptide pools in five different SP subjects. (D) Shown are
statistical analyses of the homing molecule expression on
CD154
+CD4
+ T-cells specific for SEB, CMV, and HIV (all
peptide pools) in five different SP subjects (box & whisker graph:
range and median). Mann-Whitney p-values are indicated in the
figures.
(TIF)
Figure S2 Homing potential of CD4
+ and CD8
+ T-cells
proliferating in response to HIV peptides. PBMC from SP
subjects were stimulated with different antigens and analyzed by
polychromatic flow cytometry for the expression of homing
molecules as in Figures 2 and 3. Shown are statistical analyses of
the homing molecule expression on (A) CFSE
lowCD4
+ and (B)
CFSE
lowCD8
+ T-cells specific for SEB, CMV, and HIV (all
peptide pools) in five different SP subjects (box & whisker graph:
range and median). Mann-Whitney p-values are indicated in the
figures. (C) Shown are statistical analyses of the integrin b7 and
CXCR3 co-expression on matched CD4
+ and CD8
+ T-cells
proliferating (CFSE
low) in response to CMV versus HIVNefGagPol
peptide pool in four different SP subjects. Paired T-test p-values
are indicated in the figures.
(TIF)
Figure S3 The HIV-specific CD4
+ T-cells exhibit a
Th1Th17 polarization profile. PBMCs from SP subjects were
loaded in CFSE (0.5 mM) and stimulated with different HIV Nef,
Gag, Pol peptide pools (500 ng/ml), recombinant HIV-p24 (5 mg/
ml), SEB (25 ng/ml), a peptide pool spanning the CMV pp65
protein (1 mg/ml), or C. albicans hyphae (25 ml of protein lysate) for 5
days at 37uC and further stimulated with PMA (50 ng/ml) and
Ionomycin (1 mg/ml) in the presence of Brefeldin A (10 mg/ml) for
18 hours at 37uC. Cells were stained on the surface with CD3 and
CD8 Abs as well as intracellularly with IFN-c, TNF-a, and IL-17
Abs and then analyzed by polychromatic flow cytometry for the
expression of cytokines in CD3
+CD8
2 (referred as CD4
+ T-cells)
cells. Shown is (A) the gating strategy for CD4
+ T-cells
identification and (B) representative dot plots of IFN-c, TNF-a,
and IL-17 production by HIV-specific and C. albicans-specific
CD4
+ T-cells. (C) Shown is the intracellular expression of
cytokines by CFSE
lowCD4
+ T-cells specific for SEB, CMV, C.
albicans, and different HIV peptide pools in five different SP
subjects.
(TIF)
Table S1 Screening for HIV-1 specific CD4
+ T-cells
responses using the CD154 co-culture assay. To identify
antigen-specific CD4
+ T-cells, the CD154/CD40L assay was
performed as previously described (89). To this aim, PBMC from
five HIV-infected SP subjects were stimulated with SEB (1 mg/ml),
CMV-pp65 peptide pool (5 mg/ml), recombinant HIV-p24
protein (5 mg/ml), or HIV peptide pools (10 mg/ml) in the
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PLoS ONE | www.plosone.org 16 March 2012 | Volume 7 | Issue 3 | e32964presence of anti-CD154-PE/Cy5 Abs (20 ml/well) and monensin
(2 mM) for 16 hrs at 37uC. Cells were then harvested, stained for
surface markers with fluorescence-conjugated Abs against CD3,
CD4, integrin b7, CCR6, CXCR3, and CCR4, and analyzed by
flow cytometry for the expression of homing markers on
CD3
+CD4
+CD154
+ T-cells. Results are expressed as % of
CD4
+CD154
+ T-cells. Values included in the table were .1.5-
fold higher than the background CD154 expression observed for
cells cultured in the absence of antigen.
(DOC)
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